Elevance Health, Inc. (ELV) Análisis de acciones

Descripción de la empresa

Elevance Health, Inc. operates as a comprehensive health benefits company within the United States, delivering a wide array of health plans and services to both individual consumers and employer groups through its subsidiaries. The company functions primarily within the Healthcare sector, specifically specializing in Healthcare Plans, a classification that underscores its critical role in providing essential medical coverage and administrative support services. With a market capitalization of $63.21B, an annual revenue of $199.13B, and an employee base of 96129, Elevance Health demonstrates significant economic weight and operational reach within the American insurance landscape. These valuation and revenue figures indicate that the company holds a substantial position in the industry, reflecting its ability to generate massive sales volumes and maintain a large-scale workforce necessary to manage complex health benefit portfolios.

Salud financiera

The company reported revenue of $199.13B and net income of $5.66B for the trailing twelve months, while EBITDA stood at $9.04B, revealing a distinct gap between total revenue and bottom-line profit that highlights a cost-intensive structure typical of the healthcare services industry. This disparity between the $199.13B in revenue and the $5.66B in net income suggests that operating expenses, claims payments, and administrative costs consume the majority of gross inflows, leaving a profit margin of only 2.8%. The firm generated free cash flow of $3.40B, which provides a clear indicator of its financial flexibility to fund operations, service debt, and potentially pursue strategic initiatives without relying on external financing. Regarding liquidity and leverage, the company holds $36.12B in cash against $32.75B in debt, resulting in a debt-to-equity ratio of 74.39%, which characterizes a balance sheet that maintains liquidity while utilizing leverage to finance its extensive operations. Short-term solvency is supported by a current ratio of 1.53, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Furthermore, the return on equity of 13.2% and return on assets of 4.4% demonstrate that management is effectively deploying shareholder capital and utilizing the company's asset base to generate consistent returns.

Evaluación de valoración

Valuation metrics for Elevance Health show a trailing P/E ratio of 11.36 and a forward P/E of 9.73, implying that the market expects earnings growth in the future that would justify a lower multiple compared to current historical performance. The price-to-book ratio is listed at 1.44, which indicates that the market values the company at approximately 44% above its tangible book value, suggesting a modest premium for its intangible assets and brand strength. Alternative valuation measures such as the price-to-sales ratio of 0.32 and an EV/EBITDA of 6.64 provide context that the stock trades at a fraction of its sales volume, while the EV/EBITDA suggests a relatively low multiple relative to its earnings power. The stock's price range over the last year has fluctuated between a 52-week low of $273.71 and a 52-week high of $458.75, positioning the current valuation within a broad historical band that reflects market volatility. The beta value of 0.47 indicates that the stock exhibits significantly lower price volatility relative to the broader market, making it a less sensitive instrument to general market swings compared to high-beta equities.

Growth & Income

Revenue growth stands at 9.5% year-over-year, while earnings growth is reported at 36.3%, revealing that the company's profitability is expanding at a rate substantially faster than its top-line sales, which implies improving operational efficiency or favorable margin expansion. As a dividend payer, the company offers a dividend yield of 2.4% with a payout ratio of 27.1%, indicating a highly sustainable distribution policy where only a small fraction of earnings is returned to shareholders. Given the low payout ratio, the company retains the majority of its earnings to fuel reinvestment into growth initiatives rather than distributing high dividends to the extent that would compromise future expansion capabilities. The overall growth and income profile of Elevance Health is characterized by robust earnings acceleration that outpaces revenue growth, supported by a conservative dividend approach that prioritizes capital retention for long-term strategic deployment.